MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022 - MoonLake (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale.

The company focuses on developing antibody-derived treatments for inflammatory skin conditions.

The is in preliminary talks with pharmaceutical companies interested in a potential acquisition. Citing the sources, Reuters emphasized that a deal isn't guaranteed and wished to remain anonymous.

Companies specializing in immunology have been popular acquisition targets, as indicated by recent acquisitions such as Merck & Co Inc's (NYSE:MRK) purchase of Prometheus BioSciences Inc and Eli Lilly And Co's (NYSE:LLY) acquisition of Dice Therapeutics Inc (NASDAQ:DICE).

Also Read: Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path.

Recently, MoonLake released topline results from its Phase 2 MIRA trial evaluating the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), meeting its primary endpoint.

A few days later, the company stated it had raised $400 million through a stock sale to continue funding the development of sonelokimab.

If successful, MoonLake could enter a market dominated by bigger players like Novartis AG (NYSE: NVS) and AbbVie Inc (NYSE: ABBV).

MoonLake was established in 2021 when Merck KGaA licensed the first-stage clinical development of Sonelokimab to a newly created company.

In 2022, MoonLake became a public company through a merger with a special purpose acquisition company (SPAC), raising over $200 million in cash. Since its market debut, its share price has increased fivefold.

Price Action: MLTX shares are down 7.74% at $50.07 during the premarket session on the last check Monday.

MLTXMoonLake Immunotherapeutics

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.